Zai Lab Limited (ZLAB) & NovoCure Limited (NVCR)’s TTFields Therapy Succeeds in Phase 3 Trial

Zai Lab Limited (NASDAQ:ZLAB) and NovoCure Limited (NASDAQ:NVCR) revealed landmark results from the Phase 3 PANOVA-3 trial at the 2025 ASCO Annual Meeting, marking the first therapy to show statistically significant survival improvements for unresectable, locally advanced pancreatic adenocarcinoma.

Patients receiving Tumor Treating Fields (TTFields) therapy alongside gemcitabine and nab-paclitaxel achieved a median overall survival of 16.2 months, compared to 14.2 months for chemotherapy alone—a 2.0-month increase (HR 0.82; p=0.039).

 Zai Lab Limited (ZLAB) & NovoCure Limited (NVCR)'s TTFields Therapy Meets Primary Endpoint in Phase 3 PANOVA-3 Trial

A doctor in a white coat discussing clinical trial results with a patient in an oncology practice.

The trial also demonstrated a 68.1% one-year survival rate for the TTFields group versus 60.2% for controls (p=0.029), alongside a 6.1-month extension in pain-free survival (15.2 vs. 9.1 months; HR 0.74; p=0.027). Quality-of-life metrics, including reduced pain and digestive issues, further supported the therapy’s clinical value.

“These results could redefine standards for advanced pancreatic cancer,” said Dr. Nicolas Leupin, NovoCure Limited (NASDAQ:NVCR)’s CMO, noting the therapy’s potential to address both survival and debilitating pain. Zai Lab Limited (NASDAQ:ZLAB)’s Dr. Rafael Amado emphasized urgency in bringing TTFields to China, where pancreatic cancer claims ~134,000 lives annually.

The companies plan FDA submissions in late 2025, with safety data showing only mild skin reactions linked to TTFields.

While we acknowledge the potential of ZLAB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ZLAB and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.